Copyright Reports & Markets. All rights reserved.

Global Diabetic Retinopathy Market Size, Status and Forecast 2019-2025

Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Diabetic Retinopathy Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Diabetic Retinopathy Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Laser surgery
    • 1.4.3 Injection of corticosteroids
    • 1.4.4 Anti-VEGF drugs
    • 1.4.5 Vitrectomy
  • 1.5 Market by Application
    • 1.5.1 Global Diabetic Retinopathy Market Share by Application: 2020 VS 2026
    • 1.5.2 Hospitals
    • 1.5.3 Clinics and laboratories
    • 1.5.4 Others
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Global Growth Trends

  • 2.1 Global Diabetic Retinopathy Market Perspective (2015-2026)
  • 2.2 Global Diabetic Retinopathy Growth Trends by Regions
    • 2.2.1 Diabetic Retinopathy Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Diabetic Retinopathy Historic Market Share by Regions (2015-2020)
    • 2.2.3 Diabetic Retinopathy Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Diabetic Retinopathy Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Diabetic Retinopathy Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Diabetic Retinopathy Players by Market Size
    • 3.1.1 Global Top Diabetic Retinopathy Players by Revenue (2015-2020)
    • 3.1.2 Global Diabetic Retinopathy Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Diabetic Retinopathy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Diabetic Retinopathy Market Concentration Ratio
    • 3.2.1 Global Diabetic Retinopathy Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Diabetic Retinopathy Revenue in 2019
  • 3.3 Diabetic Retinopathy Key Players Head office and Area Served
  • 3.4 Key Players Diabetic Retinopathy Product Solution and Service
  • 3.5 Date of Enter into Diabetic Retinopathy Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Diabetic Retinopathy Historic Market Size by Type (2015-2020)
  • 4.2 Global Diabetic Retinopathy Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

  • 5.1 Global Diabetic Retinopathy Market Size by Application (2015-2020)
  • 5.2 Global Diabetic Retinopathy Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Diabetic Retinopathy Market Size (2015-2020)
  • 6.2 Diabetic Retinopathy Key Players in North America (2019-2020)
  • 6.3 North America Diabetic Retinopathy Market Size by Type (2015-2020)
  • 6.4 North America Diabetic Retinopathy Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Diabetic Retinopathy Market Size (2015-2020)
  • 7.2 Diabetic Retinopathy Key Players in Europe (2019-2020)
  • 7.3 Europe Diabetic Retinopathy Market Size by Type (2015-2020)
  • 7.4 Europe Diabetic Retinopathy Market Size by Application (2015-2020)

8 China

  • 8.1 China Diabetic Retinopathy Market Size (2015-2020)
  • 8.2 Diabetic Retinopathy Key Players in China (2019-2020)
  • 8.3 China Diabetic Retinopathy Market Size by Type (2015-2020)
  • 8.4 China Diabetic Retinopathy Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Diabetic Retinopathy Market Size (2015-2020)
  • 9.2 Diabetic Retinopathy Key Players in Japan (2019-2020)
  • 9.3 Japan Diabetic Retinopathy Market Size by Type (2015-2020)
  • 9.4 Japan Diabetic Retinopathy Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Diabetic Retinopathy Market Size (2015-2020)
  • 10.2 Diabetic Retinopathy Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Diabetic Retinopathy Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Diabetic Retinopathy Market Size by Application (2015-2020)

11 India

  • 11.1 India Diabetic Retinopathy Market Size (2015-2020)
  • 11.2 Diabetic Retinopathy Key Players in India (2019-2020)
  • 11.3 India Diabetic Retinopathy Market Size by Type (2015-2020)
  • 11.4 India Diabetic Retinopathy Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Diabetic Retinopathy Market Size (2015-2020)
  • 12.2 Diabetic Retinopathy Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Diabetic Retinopathy Market Size by Type (2015-2020)
  • 12.4 Central & South America Diabetic Retinopathy Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 Bayer
    • 13.1.1 Bayer Company Details
    • 13.1.2 Bayer Business Overview
    • 13.1.3 Bayer Diabetic Retinopathy Introduction
    • 13.1.4 Bayer Revenue in Diabetic Retinopathy Business (2015-2020))
    • 13.1.5 Bayer Recent Development
  • 13.2 F. Hoffmann-La Roche
    • 13.2.1 F. Hoffmann-La Roche Company Details
    • 13.2.2 F. Hoffmann-La Roche Business Overview
    • 13.2.3 F. Hoffmann-La Roche Diabetic Retinopathy Introduction
    • 13.2.4 F. Hoffmann-La Roche Revenue in Diabetic Retinopathy Business (2015-2020)
    • 13.2.5 F. Hoffmann-La Roche Recent Development
  • 13.3 Novartis
    • 13.3.1 Novartis Company Details
    • 13.3.2 Novartis Business Overview
    • 13.3.3 Novartis Diabetic Retinopathy Introduction
    • 13.3.4 Novartis Revenue in Diabetic Retinopathy Business (2015-2020)
    • 13.3.5 Novartis Recent Development
  • 13.4 Regeneron Pharmaceuticals
    • 13.4.1 Regeneron Pharmaceuticals Company Details
    • 13.4.2 Regeneron Pharmaceuticals Business Overview
    • 13.4.3 Regeneron Pharmaceuticals Diabetic Retinopathy Introduction
    • 13.4.4 Regeneron Pharmaceuticals Revenue in Diabetic Retinopathy Business (2015-2020)
    • 13.4.5 Regeneron Pharmaceuticals Recent Development
  • 13.5 Actavis
    • 13.5.1 Actavis Company Details
    • 13.5.2 Actavis Business Overview
    • 13.5.3 Actavis Diabetic Retinopathy Introduction
    • 13.5.4 Actavis Revenue in Diabetic Retinopathy Business (2015-2020)
    • 13.5.5 Actavis Recent Development
  • 13.6 Alimera Sciences
    • 13.6.1 Alimera Sciences Company Details
    • 13.6.2 Alimera Sciences Business Overview
    • 13.6.3 Alimera Sciences Diabetic Retinopathy Introduction
    • 13.6.4 Alimera Sciences Revenue in Diabetic Retinopathy Business (2015-2020)
    • 13.6.5 Alimera Sciences Recent Development
  • 13.7 Ampio Pharmaceuticals
    • 13.7.1 Ampio Pharmaceuticals Company Details
    • 13.7.2 Ampio Pharmaceuticals Business Overview
    • 13.7.3 Ampio Pharmaceuticals Diabetic Retinopathy Introduction
    • 13.7.4 Ampio Pharmaceuticals Revenue in Diabetic Retinopathy Business (2015-2020)
    • 13.7.5 Ampio Pharmaceuticals Recent Development
  • 13.8 Antisense Therapeutics
    • 13.8.1 Antisense Therapeutics Company Details
    • 13.8.2 Antisense Therapeutics Business Overview
    • 13.8.3 Antisense Therapeutics Diabetic Retinopathy Introduction
    • 13.8.4 Antisense Therapeutics Revenue in Diabetic Retinopathy Business (2015-2020)
    • 13.8.5 Antisense Therapeutics Recent Development
  • 13.9 BCN Peptides
    • 13.9.1 BCN Peptides Company Details
    • 13.9.2 BCN Peptides Business Overview
    • 13.9.3 BCN Peptides Diabetic Retinopathy Introduction
    • 13.9.4 BCN Peptides Revenue in Diabetic Retinopathy Business (2015-2020)
    • 13.9.5 BCN Peptides Recent Development
  • 13.10 Boehringer Ingelheim
    • 13.10.1 Boehringer Ingelheim Company Details
    • 13.10.2 Boehringer Ingelheim Business Overview
    • 13.10.3 Boehringer Ingelheim Diabetic Retinopathy Introduction
    • 13.10.4 Boehringer Ingelheim Revenue in Diabetic Retinopathy Business (2015-2020)
    • 13.10.5 Boehringer Ingelheim Recent Development
  • 13.11 Glycadia
    • 10.11.1 Glycadia Company Details
    • 10.11.2 Glycadia Business Overview
    • 10.11.3 Glycadia Diabetic Retinopathy Introduction
    • 10.11.4 Glycadia Revenue in Diabetic Retinopathy Business (2015-2020)
    • 10.11.5 Glycadia Recent Development
  • 13.12 iCo Therapeutics
    • 10.12.1 iCo Therapeutics Company Details
    • 10.12.2 iCo Therapeutics Business Overview
    • 10.12.3 iCo Therapeutics Diabetic Retinopathy Introduction
    • 10.12.4 iCo Therapeutics Revenue in Diabetic Retinopathy Business (2015-2020)
    • 10.12.5 iCo Therapeutics Recent Development
  • 13.13 Isis Pharmaceuticals
    • 10.13.1 Isis Pharmaceuticals Company Details
    • 10.13.2 Isis Pharmaceuticals Business Overview
    • 10.13.3 Isis Pharmaceuticals Diabetic Retinopathy Introduction
    • 10.13.4 Isis Pharmaceuticals Revenue in Diabetic Retinopathy Business (2015-2020)
    • 10.13.5 Isis Pharmaceuticals Recent Development
  • 13.14 Kowa Group
    • 10.14.1 Kowa Group Company Details
    • 10.14.2 Kowa Group Business Overview
    • 10.14.3 Kowa Group Diabetic Retinopathy Introduction
    • 10.14.4 Kowa Group Revenue in Diabetic Retinopathy Business (2015-2020)
    • 10.14.5 Kowa Group Recent Development
  • 13.15 Lpath
    • 10.15.1 Lpath Company Details
    • 10.15.2 Lpath Business Overview
    • 10.15.3 Lpath Diabetic Retinopathy Introduction
    • 10.15.4 Lpath Revenue in Diabetic Retinopathy Business (2015-2020)
    • 10.15.5 Lpath Recent Development
  • 13.16 Numoda Capital
    • 10.16.1 Numoda Capital Company Details
    • 10.16.2 Numoda Capital Business Overview
    • 10.16.3 Numoda Capital Diabetic Retinopathy Introduction
    • 10.16.4 Numoda Capital Revenue in Diabetic Retinopathy Business (2015-2020)
    • 10.16.5 Numoda Capital Recent Development
  • 13.17 Ohr Pharmaceutical
    • 10.17.1 Ohr Pharmaceutical Company Details
    • 10.17.2 Ohr Pharmaceutical Business Overview
    • 10.17.3 Ohr Pharmaceutical Diabetic Retinopathy Introduction
    • 10.17.4 Ohr Pharmaceutical Revenue in Diabetic Retinopathy Business (2015-2020)
    • 10.17.5 Ohr Pharmaceutical Recent Development
  • 13.18 OPKO Health
    • 10.18.1 OPKO Health Company Details
    • 10.18.2 OPKO Health Business Overview
    • 10.18.3 OPKO Health Diabetic Retinopathy Introduction
    • 10.18.4 OPKO Health Revenue in Diabetic Retinopathy Business (2015-2020)
    • 10.18.5 OPKO Health Recent Development
  • 13.19 Parexel International
    • 10.19.1 Parexel International Company Details
    • 10.19.2 Parexel International Business Overview
    • 10.19.3 Parexel International Diabetic Retinopathy Introduction
    • 10.19.4 Parexel International Revenue in Diabetic Retinopathy Business (2015-2020)
    • 10.19.5 Parexel International Recent Development
  • 13.20 Promedior
    • 10.20.1 Promedior Company Details
    • 10.20.2 Promedior Business Overview
    • 10.20.3 Promedior Diabetic Retinopathy Introduction
    • 10.20.4 Promedior Revenue in Diabetic Retinopathy Business (2015-2020)
    • 10.20.5 Promedior Recent Development
  • 13.21 pSivida
    • 10.21.1 pSivida Company Details
    • 10.21.2 pSivida Business Overview
    • 10.21.3 pSivida Diabetic Retinopathy Introduction
    • 10.21.4 pSivida Revenue in Diabetic Retinopathy Business (2015-2020)
    • 10.21.5 pSivida Recent Development
  • 13.22 Quark Pharmaceuticals
    • 10.22.1 Quark Pharmaceuticals Company Details
    • 10.22.2 Quark Pharmaceuticals Business Overview
    • 10.22.3 Quark Pharmaceuticals Diabetic Retinopathy Introduction
    • 10.22.4 Quark Pharmaceuticals Revenue in Diabetic Retinopathy Business (2015-2020)
    • 10.22.5 Quark Pharmaceuticals Recent Development
  • 13.23 R-Tech Ueno
    • 10.23.1 R-Tech Ueno Company Details
    • 10.23.2 R-Tech Ueno Business Overview
    • 10.23.3 R-Tech Ueno Diabetic Retinopathy Introduction
    • 10.23.4 R-Tech Ueno Revenue in Diabetic Retinopathy Business (2015-2020)
    • 10.23.5 R-Tech Ueno Recent Development
  • 13.24 Sirnaomics
    • 10.24.1 Sirnaomics Company Details
    • 10.24.2 Sirnaomics Business Overview
    • 10.24.3 Sirnaomics Diabetic Retinopathy Introduction
    • 10.24.4 Sirnaomics Revenue in Diabetic Retinopathy Business (2015-2020)
    • 10.24.5 Sirnaomics Recent Development
  • 13.25 thromboGenics
    • 10.25.1 thromboGenics Company Details
    • 10.25.2 thromboGenics Business Overview
    • 10.25.3 thromboGenics Diabetic Retinopathy Introduction
    • 10.25.4 thromboGenics Revenue in Diabetic Retinopathy Business (2015-2020)
    • 10.25.5 thromboGenics Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    Diabetic Retinopathy market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Diabetic Retinopathy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    The key players covered in this study
    Bayer
    F. Hoffmann-La Roche
    Novartis
    Regeneron Pharmaceuticals
    Actavis
    Alimera Sciences
    Ampio Pharmaceuticals
    Antisense Therapeutics
    BCN Peptides
    Boehringer Ingelheim
    Glycadia
    iCo Therapeutics
    Isis Pharmaceuticals
    Kowa Group
    Lpath
    Numoda Capital
    Ohr Pharmaceutical
    OPKO Health
    Parexel International
    Promedior
    pSivida
    Quark Pharmaceuticals
    R-Tech Ueno
    Sirnaomics
    thromboGenics

    Market segment by Type, the product can be split into
    Laser surgery
    Injection of corticosteroids
    Anti-VEGF drugs
    Vitrectomy
    Market segment by Application, split into
    Hospitals
    Clinics and laboratories
    Others

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    Buy now